Advanced searches left 3/3

Cardiovascular - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 22 September 2022

* If you want to update the article please login/register

Early identification and treatment of women's cardiovascular risk factors prevents cardiovascular disease, saves lives, and protects future generations: Policy recommendations and take action plan utilizing policy levers

Despite efforts to raise concerns about CVD among women over the past decade, there has been stagnation in the reduction of CVD in women over the past decade, and CVD among young women and women of color has increased. Starting at 18 years ago, we recommend taking immediate action to address CVD in women, including: Promoting regular screening for risk factors including blood pressure, lipids/cholesterol, diabetes, and diabetes for all women, beginning at 18 years; With calculated atherosclerotic CVD risk score use among women 40 years or older. For those with intermediate risk per current guidelines, coronary artery calcium screening is recommended.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/clc.23921


A small‐group activity to enhance learning of cardiovascular drugs for health science students

Abstract This small-u2010group effort includes two cases in cardiovascular pharmacology to introduce students in a medical or other health professions curriculum. Students were sent with the answers 1 week ahead of time and encouraged to answer as many of the questions as possible and plan to discuss the answers with their peers at the session. 201 undergraduates at UC San Diego participated in the smallu2010group event for the 2021 academic year. Compared to 78% on other cardiovascular pharmacology questions not related to the event, students scored 84% on questions relating to the small group's session, relative to the week's activity. The facilitators' student reviews of the small-u2010group's participation were highly encouraging. Students learn the pharmacology information related to cardiovascular drugs using a small group activity with clinical scenarios, according to this study.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/prp2.1006


Obesity and contraceptive use: impact on cardiovascular risk

However, a substantial number of obese women continue to receive prescriptions of hormonal drugs that contain oestrogens for their reproductive use. In raising cardiovascular risk, there are convincing signs of an interplay between obesity and condomization. Women who are overweight or use combination oral contraceptives have a higher risk of experiencing venous thromboembolism than non-U2010COC users. The data here presented is intended to give clinicians' awareness of the cardiovascular risk in obesity-related clinical care. When prescribing hormonal contracept, the synergistic effect of obesity and COCs on deep vein thrombosis risk must be considered. Progestin-u2010only drugs are a safer alternative to COCs in patients with obesity or obesity. Obese women using condoms should be classified as a u2018at risku2019 population, and as such, they should be urged to relive their lifestyle, avoiding other cardiovascular risk factors, as a measure of primary prevention.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14104


Extracellular vesicles and their non‐coding RNA cargos: emerging players in cardiovascular disease

Exosomes, microvesicles, and apoptotic bodies have all been gaining traction recently as key mediators of cell-to-cell communication in cardiovascular disease from u2010 to u2010 cell migration. In the cardiovascular system, non-u2010coding RNAs as EV cargos have recently been investigated. Cells of the same type and from various types of cells involved in cardiovascular disease pathophysiology can be transmitted by EVu2010-derived ncRNAs. For the development of diagnostic and therapeutic tools for cardiovascular disease, a greater understanding of the specific role of EVs and their ncRNA cargos in cardiovascular function will be crucial.

Source link: https://onlinelibrary.wiley.com/doi/10.1113/JP283200


Small particles with large impact: Insights into the unresolved roles of innate immunity in extracellular vesicle‐mediated cardiovascular calcification

These calcifying EVs are a nidi for microcalcification, and can progress to the macrocalcification lesions that can be seen clinically. Inflammationu2010mediated calcification, inflammation precedes microcalcification and cell formation findings from EV release from macrophages. Local cellular crosstalk mediated by EVs, as well as circulating EVs and other inflammatory nanoparticles such as calciprotein particles and lipoproteins, are both important in cardiovascular calcification progression. To these key signaling and functional roles of these nanoparticles, it is crucial that future research integrates the now established and to be identified roles of inflammation and innate immunity in cardiovascular calcification.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/imr.13134


The role of coronary artery calcium in allocating pharmacotherapy for primary prevention of cardiovascular disease: The ABCs of CAC

The 2018 and 2019 American Heart Association/American College of Cardiology Cholesterol and Primary Prevention Guidelines as a method for refining cardiovascular disease risk assessment. We also look at the literature regarding extremely high CAC scores greater than 400 or 1000, and how these scores could indicate a risk of cardiovascular disease on par with secondary prevention cohorts.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/clc.23918


Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial

Aims People with diabetes are at a higher risk of cardiovascular disease, especially heart failures. With a weekly Incretin in Diabetes trial, we investigated the impact of incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo-controlled Research Cardiovascular Events. There was no change in either MACE or HF events with dulaglutide at baseline for participants without HF, compared to those without HF. Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo, but not so much in patients with and without HF at baseline. Regardless of baseline HF status during 5. 4 years of follow-up, Dulaglutide was not associated with a decrease in HF events in patients with type 2 diabetes in patients with type 2 diabetes.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2670


Essential nonclinical competencies for cardiovascular specialists imperatives for training

Richard Conti, a pioneer in innovation, was not limited to academic and academic fields, but also in the introduction of academicians, physicians, and trainees to various environments for the growth of their knowledge base. u2026And world view. To ensure quality for patients and develop processes that work efficiently for practitioners, physicians and all members of the care team must collaborate in an evolving environment of medical care systems, involvement in research and planning by physicians and all participants of the care team. While health-care services change, even those practitioners who remain u201cindependent require the ability to participate in system designs, processes, and planning as health care evolves. Such skill sets are not generally part of formal education, and tools to effectively contribute to such skill sets are not commonly included in such learning. This communication addresses the need for education in nonclinical skills, some existing resources, and a model for formal integration of such instruction into cardiology fellowship training.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/clc.23914


Comparative Risks of Nonsteroidal Anti‐inflammatory Drugs on Cardiovascular Diseases: A Population‐Based Cohort Study

This report aims to compare the risks in a Chinese population among nonsteroidal anti-u2010inflammatory drug users and nonusers. In Hong Kong, a retrospective cohort of 4 298 368 adults without CVD from electronic health checks between 2008 and 2017 was introduced. To determine the relationship between NSAID exposure and incident CVD, a Cox regression analysis, which also included NSAID use as a time-dependent covariate and adjusted with patient's characteristics, was done. NSAID use was shown to be significantly higher risk of CVD in comparison to non-u2010NSAID use. Except for etoricoxib, which put a higher risk, a similar CVD risk was present among users of NSAIDs, except for etoricoxib, which presented a greater danger. Given that a higher risk of CVD was consistently present among NSAID users, NSAIDs should be used cautiously, and the use of etoricoxib in the Chinese population should be investigated.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jcph.2142

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions